Since MEK acts downstream to BRAF in the MAPK pathway, a combination of BRAF and MEK inhibitors such as vemurafenib, dabrafenib, trametinib and cobimetinib have improved the effect of treatment of patients with advanced and metastatic melanoma. The gene discussed is MAP2K7; the disease is metastatic melanoma.